Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

Real time quantitative PCR.Preprint

Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works

A novel method for real time quantitative RT-PCR.Preprint

Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090 · see citing works

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,593 · see citing works

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341 · see citing works

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001 · see citing works

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996 · see citing works

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980 · see citing works

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834 · see citing works

EGF receptor

Wells, A. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00015-1 · Cited by 819 · see citing works

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770 · see citing works

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766 · see citing works

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · see citing works

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Pegram, M. D., Hsu, S., Lewis, G., Pietras, R. J., Beryt, M., Sliwkowski, M. X., Coombs, D., Baly, D. L., Kabbinavar, F. F., & Slamon, D. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 693 · see citing works

ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674 · see citing works

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653 · see citing works

Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., FENDLY, B. M., Cerione, R. A., VANDLEN, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 644 · see citing works

From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

Yeh, S., Lin, H., Kang, H., Thin, T. H., Lin, M., & Chang, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5458 · Cited by 594 · see citing works

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548 · see citing works

Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer

Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548 · see citing works

Smart drugs: Tyrosine kinase inhibitors in cancer therapy

Shawver, L. K., Slamon, D. J., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 524 · see citing works

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.

Soltoff, S. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550 · Cited by 515 · see citing works

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

Wen, Y., Hu, M. C. ‐., Makino, K., Spohn, B., Bartholomeusz, G. A., Yan, D., & Hung, M. (2000) · PubMed · Cited by 461 · see citing works

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455 · see citing works

Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential

Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F. O., Natali, P. G., Brunetti, M., Aiello, F. B., & Piantelli, M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4 · Cited by 441 · see citing works

Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

Lenferink, A. E. G., Pinkas‐Kramarski, R., van de Poll, M. L. M., van Vugt, M. J. H., Klapper, L. N., Tzahar, E., Waterman, H., Sela, M., van Zoelen, E. J. J., & Yarden, Y. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413 · see citing works

Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406 · see citing works

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

FENDLY, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., & Ullrich, A. (1990) · PubMed · Cited by 403 · see citing works

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Arteaga, C. L. (2001) · PubMed · Cited by 397 · see citing works

Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer

Signoretti, S. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397 · see citing works

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 387 · see citing works

Binding specificities and affinities of egf domains for ErbB receptors

Jones, J. T., Akita, R. W., & Sliwkowski, M. X. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00283-5 · Cited by 387 · see citing works

ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors

Worthylake, R. A., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 326 · see citing works

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

Cunha, G. R. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3+ · Cited by 321 · see citing works

Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities

Beerli, R. R., & Hynes, N. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6071 · Cited by 308 · see citing works

ZD1839 (???Iressa???)*,??? as an Anticancer Agent

Baselga, J., & Averbuch, S. D. (2000) · Drugs · doi:10.2165/00003495-200060001-00004 · Cited by 303 · see citing works

ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner

Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262 · see citing works

Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence

Agus, D. B., Cordon‐Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., & Scher, H. I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1869 · Cited by 248 · see citing works

Untitled work

(1996) · PubMed · Cited by 238 · see citing works

CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Wainstein, M. A., He, F., Robinson, D. R., Kung, H., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., & Kursh, E. D. (1994) · PubMed · Cited by 225 · see citing works

Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

Scher, H. I., Sarkis, A. S., Reuter, V., Cohen, D., Netto, G. J., Petrylak, D. P., LIANES, P., FUKS, Z. Y., Mendelsohn, J. M., & Cordon‐Cardo, C. (1995) · PubMed · Cited by 214 · see citing works

The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands

Tzahar, E. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00032-2 · Cited by 192 · see citing works

Epidermal growth factor receptor

Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T., Ward, C. W., & Burgess, A. W. (2003) · Elsevier eBooks · doi:10.1016/b978-012160281-9/50004-9 · Cited by 188 · see citing works

Heparin Blockade of Thrombin-Induced Smooth Muscle Cell Migration Involves Inhibition of Epidermal Growth Factor (EGF) Receptor Transactivation by Heparin-Binding EGF-Like Growth Factor

Kalmes, A., Vesti, B. R., Daum, G., Abraham, J. A., & Clowes, A. W. (2000) · Circulation Research · doi:10.1161/01.res.87.2.92 · Cited by 182 · see citing works

Neu Differentiation Factor Activation of ErbB-3 and ErbB-4 Is Cell Specific and Displays a Differential Requirement for ErbB-2

Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6496 · Cited by 182 · see citing works

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

Osman, I., Scher, H. I., Drobnjak, M., Verbel, D., Morris, M. J., Agus, D. B., Ross, J. S., & Cordon‐Cardo, C. (2001) · PubMed · Cited by 161 · see citing works

Intracellular expression of single chain antibodies reverts ErbB-2 transformation.

Beerli, R. R., Wels, W. S., & Hynes, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51027-4 · Cited by 155 · see citing works

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M. J., Cordon‐Cardo, C., & Golde, D. W. (1999) · PubMed · Cited by 143 · see citing works

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., FENDLY, B. M., Bauer, K. D., & Sliwkowski, M. X. (1996) · PubMed · Cited by 140 · see citing works

HER-2/NEU EXPRESSION IN PROSTATE CANCER: HIGH LEVEL OF EXPRESSION ASSOCIATED WITH EXPOSURE TO HORMONE THERAPY AND ANDROGEN INDEPENDENT DISEASE

Shi, Y., Brands, F., CHATTERJEE, S., Feng, A., Groshen, S. G., Schewe, J., Lieskovsky, G., & Côté, R. J. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65822-3 · Cited by 122 · see citing works

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

Ross, J. S., Sheehan, C., Hayner‐Buchan, A., Ambros, R. A., Kallakury, B., Kaufman, R. P., Fisher, H. A. �., & Muraca, P. J. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90157-x · Cited by 105 · see citing works

γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175

Schaefer, G., Fitzpatrick, V. D., & Sliwkowski, M. X. (1997) · Oncogene · doi:10.1038/sj.onc.1201317 · Cited by 104 · see citing works

EGF receptor signaling in prostate morphogenesis and tumorigenesis.

Kim, H. G., Kassis, J. N., Souto, J. C. S., Turner, T., & Wells, A. H. (1999) · PubMed · doi:10.14670/hh-14.1175 · Cited by 100 · see citing works

NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.

Marte, B. M., Graus-Porta, D., Jeschke, M. G., Fabbro, D., Hynes, N. E., & Taverna, D. (1995) · PubMed · Cited by 98 · see citing works

Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments

Kelley, R. F., O'Connell, M. P., Carter, P. M., Presta, L. G., Eigenbrot, C. W., Covarrubias, M., Snedecor, B., Bourell, J. H., & Vetterlein, D. (1992) · Biochemistry · doi:10.1021/bi00139a003 · Cited by 96 · see citing works

Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer

Savinainen, K., Saramäki, O. R., Linja, M. J., Ola Bratt, A., Tammela, T. L. J., Isola, J. J., & Visakorpi, T. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64377-5 · Cited by 90 · see citing works

HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer

Reese, D., Small, E. J., Magrane, G., Waldman, F. M., Chew, K., & Sudilovsky, D. (2001) · American Journal of Clinical Pathology · doi:10.1309/vxkk-yvrh-9b11-ydpt · Cited by 79 · see citing works

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.

Kallakury, B., Sheehan, C. E., Ambros, R. A., Fisher, H., Kaufman, R. P., Muraca, P. J., & Ross, J. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1302 · Cited by 70 · see citing works

Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.

Tørring, N., Pe, J., Bs, S., & Nexø, E. (2000) · PubMed · Cited by 68 · see citing works

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4

Fitzpatrick, V. D., Pisacane, P. I., VANDLEN, R. L., & Sliwkowski, M. X. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00737-6 · Cited by 67 · see citing works

Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis

Jones, J. T., Ballinger, M. D., Pisacane, P. I., Lofgren, J. A., Fitzpatrick, V. D., Fairbrother, W. J., Wells, J. A., & Sliwkowski, M. X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11667 · Cited by 57 · see citing works

Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation.

Lw, C. (1993) · PubMed · Cited by 51 · see citing works

Amphiregulin Is Coordinately Expressed with Heparin-Binding Epidermal Growth Factor-Like Growth Factor in the Interstitial Smooth Muscle of the Human Prostate1

Adam, R. M., Borer, J. G., Williams, B. J., Eastham, J. A., Loughlin, K. R., & Freeman, M. R. (1999) · Endocrinology · doi:10.1210/endo.140.12.7221 · Cited by 49 · see citing works

A potential role for activated HER-2 in prostate cancer.

Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., & Sliwkowski, M. X. (2000) · PubMed · Cited by 41 · see citing works

Her-2/neu oncogene amplification in clinically localised prostate cancer

Oxley, J., Winkler, M. H., Gillatt, D. A., & Peat, D. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.2.118 · Cited by 40 · see citing works

Inhibitors of Tyrosine Kinases in the Treatment of Psoriasis

Ben‐Bassat, H., & Klein, B. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400182 · Cited by 39 · see citing works

Stromal-epithelial interactions in breast cancer

Cullen, K. J., & Lippman, M. E. (1991) · Cancer treatment and research · doi:10.1007/978-1-4615-3500-3_20 · Cited by 31 · see citing works

Analysis of Heregulin-Induced ErbB2 Phosphorylation with a High-Throughput Kinase Receptor Activation Enzyme-Linked Immunosorbant Assay

Sadick, M. D., Sliwkowski, M. X., Nuijens, A., Bald, L. N., Chiang, N., Lofgren, J. A., & Wong, W. L. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0114 · Cited by 26 · see citing works

HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR IS AN AUTOCRINE MEDIATOR OF HUMAN PROSTATE STROMAL CELL GROWTH IN VITRO

Duque, J. L. F., Adam, R. M., Mullen, J. S., Lin, J., Richie, J. P., & Freeman, M. R. (2001) · The Journal of Urology · doi:10.1097/00005392-200101000-00080 · Cited by 11 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · see citing works

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,387 · see citing works

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works

The ErbB/HER family of protein-tyrosine kinases and cancer

Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,365 · see citing works

Deconstructing the molecular portraits of breast cancer

Prat, A., & Perou, C. M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,345 · see citing works

The discovery of receptor tyrosine kinases: targets for cancer therapy

Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · see citing works

Targeting HER2-positive breast cancer: advances and future directions

Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160 · see citing works

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,144 · see citing works

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,123 · see citing works

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis

Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · see citing works

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · see citing works

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952 · see citing works

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nahta, R., Yu, D., Hung, M., Hortobágyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916 · see citing works

An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

Burgess, A. W., Cho, H., Eigenbrot, C. W., Ferguson, K. M., Garrett, T., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 908 · see citing works

Treatment of HER2-positive breast cancer: current status and future perspectives

Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 860 · see citing works

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829 · see citing works

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Tarantino, P., Hamilton, E. P., Tolaney, S. M., Cortés, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 804 · see citing works

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793 · see citing works

Deciphering breast cancer: from biology to the clinic

Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 761 · see citing works

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

Baselga, J. M., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 721 · see citing works

Epidermal Growth Factor Receptor Targeting in Cancer

Mendelsohn, J. M., & Baselga, J. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693 · see citing works

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

Baselga, J. M., Gelmon, K. A., Verma, S., Wardley, A. M., Conte, P., Miles, D. W., Bianchi, G., Cortés, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643 · see citing works

ErbB Receptors: Directing Key Signaling Networks Throughout Life

Holbro, T., & Hynes, N. E. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 642 · see citing works

A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T. Q., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 632 · see citing works

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 627 · see citing works

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

Scheuer, W., Friess, T., BURTSCHER, H. J., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 624 · see citing works

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607 · see citing works

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 606 · see citing works

The role of HER2 in cancer therapy and targeted drug delivery

Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 557 · see citing works

Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line

Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J. J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 525 · see citing works

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Mitri, Z. I., Constantine, T., & O'Regan, R. M. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 520 · see citing works

Resistance to Trastuzumab in Breast Cancer

Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 506 · see citing works

Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin

Austin, C. D., Mazière, A. M. G. L. D., Pisacane, P. I., van Dijk, S., Eigenbrot, C. W., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 498 · see citing works

Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497 · see citing works

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Spector, N. L., & Blackwell, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497 · see citing works

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494 · see citing works

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, S. E., Narasanna, A., Pérez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G. F., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 474 · see citing works

Herceptin: mechanisms of action and resistance

Nahta, R., & Esteva, F. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446 · see citing works

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 451 · see citing works

The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

Chan, C., Li, C., Yang, W., Gao, Y., Lee, S.-W., Feng, Z., Huang, H.-Y., Tsai, K. K., Flores, L. G., Shao, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.065 · Cited by 434 · see citing works

HER2 therapy: Molecular mechanisms of trastuzumab resistance

Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433 · see citing works

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3148 · Cited by 415 · see citing works

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390 · see citing works

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 372 · see citing works

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

Baselga, J. M., Cortés, J., Im, S., Clark, E., Ross, G. A., Kiermaier, A. C., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364 · see citing works

Spatial regulation of receptor tyrosine kinases in development and cancer

Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 362 · see citing works

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 358 · see citing works

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · see citing works

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341 · see citing works

Trastuzumab: triumphs and tribulations

Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 336 · see citing works

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

O’Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J. P., O’Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324 · see citing works

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

Adams, C. W., Allison, D. E., Flagella, K. M., Presta, L. G., Clarke, J. B., Dybdal, N. O., McKeever, K., & Sliwkowski, M. X. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316 · see citing works

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems

Bird, B., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 306 · see citing works

Mechanisms for oncogenic activation of the epidermal growth factor receptor

Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M., & Poulsen, H. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.023 · Cited by 303 · see citing works

Antitumour immunity regulated by aberrant ERBB family signalling

Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 279 · see citing works

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Luen, S. J., Salgado, R., Fox, S. B., Savas, P. S., Eng‐Wong, J., Clark, E., Kiermaier, A. C., Swain, S. M., Baselga, J. M., Michiels, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 276 · see citing works

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutiérrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274 · see citing works

Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer

Tanner, M., Kapanen, A. I., Junttila, T. T., Raheem, O., Grénman, S., Elo, J. P., Elenius, K., & Isola, J. J. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1585.3.12 · Cited by 272 · see citing works

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Gianni, L., Lladó, A., Bianchi, G., Cortés, J., Kellokumpu‐Lehtinen, P., Cameron, D., Miles, D. W., Salvagni, S., Wardley, A. M., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262 · see citing works

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J. A. J., Pulkkinen, J. O., Grenman, R. A., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 257 · see citing works

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Xia, W., Gerard, C. M., Liu, L.-H., Baudson, N., Ory, T., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258 · see citing works

Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications

Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257 · see citing works

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Gordon, M. S., Matei, D. E., Aghajanian, C. A., Matulonis, U. A., BREWER, M. A., Fleming, G. F., Hainsworth, J. D., García, A. A., Pegram, M. D., Schilder, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4221 · Cited by 252 · see citing works

Targeting HER1/EGFR: A molecular approach to cancer therapy

Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70010-4 · Cited by 250 · see citing works

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cortés, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K. A., Pivot, X. B., Verma, S., Albanell, J., Conte, P., Lluch, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 250 · see citing works

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X.-H., Esteva, F. J., & Liu, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3321 · Cited by 244 · see citing works

The ERBB3 receptor in cancer and cancer gene therapy

Sithanandam, G., & Anderson, L. M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.15 · Cited by 240 · see citing works

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., Gonzalez-Angulo, A. M., Mills, G. B., Penuel, E. M., Winslow, J. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1872 · Cited by 228 · see citing works

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

French, D., Lin, B. C., Wang, M.-T., Adams, C. W., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216 · see citing works

Drug delivery approaches for breast cancer

Singh, S. K., Singh, S., Lillard, J. W., & Singh, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140325 · Cited by 220 · see citing works

Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4

Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 219 · see citing works

Ligand-induced ErbB receptor dimerization

Lemmon, M. A. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.024 · Cited by 216 · see citing works

Her2-positive breast cancer: Herceptin and beyond

Dean-Colomb, W. M., & Esteva, F. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.013 · Cited by 208 · see citing works

Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer

Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., & Wilson, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307649200 · Cited by 201 · see citing works

Molecular Pathways: HER3 Targeted Therapy

Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 197 · see citing works

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D. J., Schaefer, G., Miller, K. D., André, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198 · see citing works

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 192 · see citing works

Targeting the function of the HER2 oncogene in human cancer therapeutics

Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190 · see citing works

Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3

Chen, C. B., Chernis, G. A., Hoang, V. Q., & Landgraf, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332660100 · Cited by 190 · see citing works

HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

English, D. P.-G., Roque, D. M., & Santin, A. D. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0024-9 · Cited by 188 · see citing works

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Campbell, M. R., Amin, D. N., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 187 · see citing works

Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

Arpino, G., Gutiérrez, C., Weiss, H. L., Rimawi, M. F., Massarweh, S. A., Bharwani, L. D., Placido, S. D., Osborne, C. K., & Schiff, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk151 · Cited by 188 · see citing works

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Makhija, S. K., Amler, L. C., Glenn, D., Ueland, F. R., Gold, M. A., Dizon, D. S., Paton, V. E., Lin, C., Januario, T., Ng, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3354 · Cited by 186 · see citing works

Targeting of erbB3 receptor to overcome resistance in cancer treatment

Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 176 · see citing works

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 179 · see citing works

HER-2-targeted therapy: lessons learned and future directions.

Nahta, R., & Esteva, F. J. (2003) · PubMed · Cited by 178 · see citing works

Microfluidic Immuno-Biochip for Detection of Breast Cancer Biomarkers Using Hierarchical Composite of Porous Graphene and Titanium Dioxide Nanofibers

Ali, M. A., Mondal, K., Jiao, Y., Oren, S., Xu, Z., Sharma, A., & Dong, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b05648 · Cited by 177 · see citing works

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium

Fuller, S. J., Sivarajah, K., & Sugden, P. H. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.02.278 · Cited by 175 · see citing works

HER3 signaling and targeted therapy in cancer

Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175 · see citing works

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y., & Sela, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812059106 · Cited by 173 · see citing works

Mechanisms of action of therapeutic antibodies for cancer

Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171 · see citing works

Monoclonal antibodies for the treatment of cancer

Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 172 · see citing works

The Mysterious Ways of ErbB2/HER2 Trafficking

Bertelsen, V., & Stang, E. (2014) · Membranes · doi:10.3390/membranes4030424 · Cited by 172 · see citing works

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 168 · see citing works

Pertuzumab: new hope for patients with HER2-positive breast cancer

Capelán, M., Pugliano, L., de Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C. P., Loi, S., & Piccart, M. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 167 · see citing works

Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab

Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J. S., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 165 · see citing works

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D. W., Knott, A., Clark, E., Benyunes, M. C., Ross, G. A., & Baselga, J. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0448 · Cited by 163 · see citing works

Stop signals

Greenwood, E. (2002) · Nature reviews. Cancer · doi:10.1038/nrc892

Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects

Jackson, J. G., Clair, P. S., Sliwkowski, M. X., & Brattain, M. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3106 · Cited by 104 · see citing works

Changes in heregulin β1 (HRGβ1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line

Yoo, J.-Y., & Hamburger, A. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00004-5 · Cited by 7 · see citing works

Erb-2/HER2 Oncogene in Breast Cancer: Does Bivalency of Growth Factors Drive Tumorigenicity Through Receptor Heterodimerization

Yarden, Y. (1999) · doi:10.21236/ada382955

Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

Grunt, T. W., Saceda, M., Martin, M. B., Lupu, R., Dittrich, E., Krupitza, G., Harant, H., Huber, H. P., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630417 · Cited by 70 · see citing works